ITV

Tag: Type 2 Diabetes

  • Morepen Laboratories’ sugar-busting bargain hits Indian market

    Morepen Laboratories’ sugar-busting bargain hits Indian market

    MUMBAI: Morepen Laboratories has unleashed Empamore, a wallet-friendly weapon against Type 2 diabetes, heart failure and kidney disease that promises to shake up treatment for millions in the world’s diabetes capital.

    With India groaning under the weight of 101 million diabetes cases, the pharmaceutical firm’s latest offering aims to deliver the same therapeutic punch as pricier alternatives at a fraction of the cost—a sweet deal for patients previously priced out of optimal care.

    The new drug, empagliflozin, belongs to the coveted class of SGLT2 inhibitors and will be available in various formulations, including combinations with metformin. All products are manufactured at Morepen’s facilities, which boast the American regulator’s stamp of approval.

    “At Morepen, we are dedicated to democratising healthcare by making world-class treatments accessible to all,” declared vice president of sales & marketing Ashutosh Sharma. “With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90 per cent lower cost than existing brands, helping millions manage their condition effectively without financial strain.”

    This aggressive pricing strategy aims to capture a hefty slice of India’s diabetes market, which is expected to grow at a robust 10.9 per cent compound annual growth rate as pre-diabetes cases swell to a staggering 136 million.

    Morepen is no newcomer to the diabetes battleground. The company has already flooded the market with more than 12.33 million glucometers and a mind-boggling 1.65 billion blood glucose strips, establishing itself as a familiar name in medicine cabinets across the subcontinent.

    The firm’s latest offering promises more than just glycaemic control, addressing cardiovascular and renal complications while packaging the pills in perforated strips for patients who might otherwise struggle with adherence.

    With a global footprint spanning 82 countries, Morepen’s bargain-basement diabetes treatment may soon be sweetening the lives of patients far beyond Indian shores—proving that sometimes, the best medicine is the one you can actually afford.

  • Republic Media Network, BeatO team up for diabetes awareness campaign

    Republic Media Network, BeatO team up for diabetes awareness campaign

    Mumbai: Republic Media Network and BeatO have come together to launch the social campaign called ‘India Beats Diabetes.’ The campaign focuses on showcasing facts about diabetes, breaking myths, and starting conversations with the masses to drive better health outcomes in the country.

    Through this campaign, BeatO aims at enabling people with diabetes and pre-diabetes to effectively control and reduce the severity of the condition, with the knowledge and expertise of top doctors and coaches from BeatO, said the statement.

    “The prevalence of diabetes in India is enormous. The general awareness of the condition in the country is low, which results in a significant effect on the number of complications that people experience,” stated Republic Media Network MD and editor-in-chief Arnab Goswami. “There is an urgency for a sustained conversation on this subject; creating awareness on diabetes and the necessary measures required to battle it. Republic stands tall with partners who dedicate themselves to a social cause.”

    “Gautam, Yash, and Kunal have a vision and they are here to revolutionise the path of access to healthcare for people across the nation, and we at Republic will support it in every possible way,” he further said.

    In India, more than 77 million adults live with diabetes. Researchers predict that this number will change to 134 million by 2045. High prevalence and the expected rise in lifestyle conditions call for an urgent need for all stakeholders to drive awareness of proper diabetes management and care.

    Research also estimates that 57 per cent of cases of diabetes remain undiagnosed. This is highly alarming, as the risk of complications increases when one avoids medication to control blood sugar regularly.

    At BeatO, our vision is to support every Indian family to beat diabetes. BeatO gives the power to prevent, control, and reverse diabetes into the hands of millions of Indians. We do this through our smartphone-connected glucometer and app that provides personalised insights and timely guidance by medical experts,” said BeatO co-founder and CEO Gautam Chopra. “This partnership with Republic will help us bring the same in-depth knowledge and expertise in diabetes care, control, and reversal (type 2 diabetes) to empower people across the country to manage the condition.”

    “At BeatO, we are working to alleviate the burden of chronic diseases to make sure India beats diabetes. Today when we face unprecedented challenges in the health sector, we at BeatO are taking diabetes management one step further and are now able to offer highly personalized care for type 2 Diabetes reversal – which addresses the root cause of diabetes- insulin resistance and carb intolerance,” added BeatO co-founder and COO Yash Sehgal.